MAXIMIZING WEIGHT LOSS AFTER BARIATRIC SURGERY: THE ROLE OF SEMAGLUTIDE
The Role of Semaglutide in Post-Bariatric Weight Management
Weight loss surgery is becoming increasingly popular, with over 250,000 individuals undergoing bariatric surgery each year in the United States alone. However, around 20% to 30% of these individuals may experience insufficient weight loss or regain weight post-surgery. While lifestyle changes like diet and exercise are beneficial, managing post-bariatric weight regain has posed challenges. Recent research indicates that incorporating GLP-1 agonist medications like semaglutide (available as Ozempic and Wegovy) into post-bariatric regimens can effectively address weight regain and support long-term weight loss.
Understanding Semaglutide
Semaglutide, the active ingredient in Ozempic and Wegovy, was initially introduced for the treatment of type 2 diabetes. Administered weekly via injection, semaglutide mimics the action of glucagon-like peptide 1 (GLP-1), a hormone that stimulates insulin release and promotes satiety. The medication slows down digestion, controls appetite, and helps regulate blood sugar levels.
Recognizing the weight loss benefits observed in individuals using Ozempic, the manufacturer sought FDA approval for semaglutide as a weight loss drug under the brand name Wegovy. Semaglutide can now be prescribed for weight loss, with studies demonstrating significant weight reduction.
Weight Loss with Semaglutide
Studies have shown that individuals receiving weekly injections of 2.4 mg of semaglutide can achieve an average weight loss of nearly 15% of their body weight within a year and a half. Apart from appetite control, semaglutide offers sustained benefits by reducing cravings for certain foods, making it easier to resist temptations.
Semaglutide After Bariatric Surgery
Gastric sleeve and gastric bypass surgeries are effective weight loss interventions, but some individuals experience weight regain afterward. GLP-1 medications like Wegovy and Ozempic can help address this issue. Research indicates that individuals who regained weight post-bariatric surgery lost approximately two-thirds of the regained weight after starting semaglutide treatment.
Studies have also compared the effectiveness of semaglutide against other weight loss drugs or lifestyle changes in reducing post-bariatric weight regain. Semaglutide consistently proved to be more effective and faster in promoting weight loss.
Safety Considerations
While semaglutide offers significant benefits, it may not be suitable for everyone. Individuals with a history of certain health conditions, such as thyroid cancer, pancreatitis, or kidney problems, should exercise caution when using semaglutide. Healthcare providers can provide personalized guidance on the suitability of semaglutide based on individual health conditions and medications.
Benefits of Weight Loss
Weight loss offers numerous benefits beyond physical appearance. It can reduce the risk of conditions like cancer, improve quality of life, and alleviate obesity-related health issues such as osteoarthritis and sleep apnea. GLP-1 medications like semaglutide not only aid in weight loss but also improve physical functioning and regulate cardiometabolic risk factors like high blood pressure and elevated cholesterol.
Similarly, bariatric surgery offers more than just weight loss. It significantly reduces the risk of stroke or heart attack, relieves obesity-related health conditions, and enhances overall quality of life.
Conclusion
Incorporating GLP-1 medications like semaglutide into post-bariatric surgery regimens can effectively address weight regain and support long-term weight loss. However, it’s essential to consult healthcare providers to determine the suitability of semaglutide based on individual health conditions and medications. Weight loss, whether achieved through medication, surgery, or lifestyle changes, offers significant health benefits, highlighting the importance of personalized approaches to weight management.
Disclaimer
The information provided in this blog post is for educational purposes only and does not replace professional medical advice. While based on peer-reviewed research and information from reputable sources, it is not a substitute for consultation with healthcare providers. Individuals should consult their healthcare providers for personalized medical advice, diagnosis, or treatment regarding weight management or any health concerns.
Sources:
- Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., … & Jensen, C. B. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22.
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Finer, N. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
- Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., … & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.
- Courcoulas, A. P., Belle, S. H., Neiberg, R. H., Pierson, S. K., Eagleton, J. K., Kalarchian, M. A., … & Jakicic, J. M. (2014). Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment. JAMA surgery, 149(7), 716-722.
- Magkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., … & Klein, S. (2016). Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell metabolism, 23(4), 591-601.